Obatoclax antagonizes Mcl-1 and induces cell death in hematological tumors [11,12], so we decided to study obatoclax effects in paclitaxel-sensitive and paclitaxel-resistant bladder cancer cells. Here, MCL1 is linked to urinary bladder cancer.